Sotera Health (NASDAQ:SHC) Receives $16.50 Consensus Target Price from Brokerages

Sotera Health (NASDAQ:SHC) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $16.50.

Several research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Tuesday, August 6th. Citigroup upped their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Barclays upped their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th.

Sotera Health Trading Down 4.5 %

Shares of SHC opened at $14.31 on Thursday. The firm’s 50-day moving average price is $15.94 and its 200-day moving average price is $13.87. The firm has a market capitalization of $4.05 billion, a price-to-earnings ratio of 57.24 and a beta of 2.08. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. The business had revenue of $285.47 million for the quarter, compared to the consensus estimate of $278.64 million. During the same period in the previous year, the firm earned $0.18 EPS. The company’s revenue was up 8.5% on a year-over-year basis. Sell-side analysts anticipate that Sotera Health will post 0.61 EPS for the current year.

Insider Activity

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 55.12% of the stock is owned by corporate insiders.

Institutional Trading of Sotera Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CWM LLC increased its stake in shares of Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after purchasing an additional 993 shares in the last quarter. True Wealth Design LLC purchased a new stake in shares of Sotera Health in the third quarter worth $32,000. GAMMA Investing LLC increased its stake in shares of Sotera Health by 125.0% in the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after purchasing an additional 1,660 shares in the last quarter. Point72 DIFC Ltd increased its stake in shares of Sotera Health by 556.6% in the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after purchasing an additional 5,544 shares in the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Sotera Health in the third quarter worth $91,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.